Literature DB >> 9479878

Usefulness of FDG-PET in diagnosing primary lymphoma of the liver.

M Bangerter1, F Moog, M Griesshammer, E Merkle, M Hafner, V Ellenrieder, S N Reske, H Heimpel.   

Abstract

This case report shows for the first time the usefulness of positron emission tomography (PET) with 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) in the diagnosis of primary non Hodgkin's lymphoma of the liver. Results of FDG-PET, which in contrast to other imaging techniques offers the advantage of screening the whole body, demonstrated a high glycolytic activity of a solitary mass in the liver with central necrosis (loss of glycolytic activity), but no spread of lymphoma to the body. These results were confirmed by ultrasound, computed tomography, magnetic resonance imaging and were biopsy proven. From our findings we conclude that in patients with liver masses with high uptake of FDG, lack of liver dysfunction and absence of signs indicating other malignancies, a primary lymphoma of the liver should be considered as a possible diagnosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9479878     DOI: 10.1016/s0925-5710(97)00068-6

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  3 in total

1.  FDG PET/CT diagnosis of hepatic lymphoma mimicking focal fatty infiltration on CT.

Authors:  Eugene Lin; Marie Lee; Nicholas Agoff
Journal:  J Radiol Case Rep       Date:  2010-04-01

2.  Primary hepatic lymphoma in a patient with previous rectal adenocarcinoma: a case report and discussion of etiopathogenesis and diagnostic tools.

Authors:  Lucia Raimondo; Idalucia Ferrara; Alfonso De Stefano; Chiara Alessandra Cella; Francesco Paolo D'Armiento; Giuseppe Ciancia; Roberto Moretto; Amalia De Renzo; Chiara Carlomagno
Journal:  Int J Hematol       Date:  2012-02-21       Impact factor: 2.490

3.  ¹⁸F-fluorodeoxyglucose PET/CT findings of a solitary primary hepatic lymphoma: a case report.

Authors:  Bo Pan; Cun-Shi Wang; Jian-Kui Han; Lin-Feng Zhan; Ming Ni; Shi-Cheng Xu
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.